ArticleJournal of the American Society of Hypertension : JASH
Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified.
Article in Journal of the American Society of Hypertension : JASH. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Executive Summary of the 2024 Philippine Clinical Practice Guidelines on the Diagnosis and Management of Acute Severe Blood Pressure Elevation.Journal of clinical hypertension (Greenwich, Conn.) · 2026Guideline
- Physicians' Beliefs About Treating Asymptomatic Elevated Blood Pressure Readings Among Hospitalized Patients.Journal of general internal medicine · 2026Article
- Stopping or continuing chronic antihypertensive therapy during hospitalization.Journal of internal medicine · 2026Article
- Reducing the Nonindicated Use of IV Hydralazine in the Inpatient Setting.JACC. Case reports · 2025Article
- Considering Adverse Effects of Common Antihypertensive Medications in the ED.Current hypertension reports · 2024Review
- Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents.International journal of hypertension · 2024Review
- Clinical utility of routine investigations and risk factors of end-organ damage in asymptomatic severe hypertension.Internal and emergency medicine · 2023Article
- Article
- Noncardiac inpatient has acute hypertension: Treat or not?The Journal of family practice · 2022Article
- Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension.PloS one · 2022Article
- Pro Re Nata Antihypertensive Medications and Adverse Outcomes in Hospitalized Patients: A Propensity-Matched Cohort Study.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.BMJ open quality · 2019Article
- Institutional Pathways to Improve Care of Patients with Elevated Blood Pressure in the Emergency Department.Current hypertension reports · 2018Review
- Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.Therapeutic advances in cardiovascular disease · 2018Article
- An Update on Inpatient Hypertension Management.Current cardiology reports · 2015Review
- The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child.Pediatric nephrology (Berlin, Germany) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Due to observations of increased off-label use of intravenous hydralazine in area hospitals, we studied its use in a university teaching hospital. Patients were prospectively identified between April and October 2010 with a pharmacy order for intravenous hydralazine. Demographic and clinical information, including pretreatment blood pressure (BP), change in BP and heart rate within 2 hours after administration of hydralazine, and adverse events were obtained. Ninety-four patients (mean age, 69 ± 18 years, 48% women, 89% with known hypertension) received 201 intravenous hydralazine doses (mean dose of 11.4 ± 4.3 mg). Only 4 (2%) patients had evidence of an urgent hypertensive condition. Following hydralazine, BP was reduced by 24/9 ± 29/15 mmHg and heart rate increased by 4 ± 13 beats per minute. Changes from baseline in BP were related to baseline BP. Seventeen patients experienced an adverse event, the most common being hypotension (n = 11). Intravenous hydralazine is commonly prescribed for non-urgent cases of hypertension in the hospitalized patient. While changes in systolic BP are related to baseline BP values, they are highly variable, and associated with hypotension. Thus, this agent may not be useful for treating hypertension in many hospitalized patients and may cause harm if used inappropriately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.